Malini Harigopal, MD
DownloadHi-Res Photo
Cards
About
Titles
Professor Adjunct in Pathology
Director of Immunohistochemistry Lab, PathologyBiography
Dr. Harigopal completed her residency in Anatomic and Clinical Pathology at the University of Chicago in 2001, followed by a fellowship in cytopathology at New York Presbyterian Hospital. Dr. Harigopal also completed fellowships in breast pathology, cytopathology and renal pathology at New York Presbyterian. She is a board-certified cytopathologist.
Appointments
Pathology
Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Fellow
- New York Presbyterian Hospital (2016)
- Fellow
- New York Presbyterian Hospital (2002)
- Fellow
- New York Presbyterian Hospital (2001)
- Resident
- University of Chicago Medical Center (2000)
- Resident
- Brooklyn Hospital (1997)
- MD
- Gandhi Medical College (1985)
Research
Overview
Biomarker studies in breast cancer and pancreatic cancers using an objective and quantitative method of analysis (AQUA) in tissue microarrays.
Medical Subject Headings (MeSH)
Breast; Breast Neoplasms; Immunohistochemistry; Microarray Analysis; Pathology; Thyroid Gland
Research at a Glance
Yale Co-Authors
Frequent collaborators of Malini Harigopal's published research.
Publications Timeline
A big-picture view of Malini Harigopal's research output by year.
Research Interests
Research topics Malini Harigopal is interested in exploring.
David Rimm, MD, PhD
Angelique W. Levi, MD
Robert Camp, PhD, MD
Lajos Pusztai, MD, DPhil
Uma Krishnamurti, MD, MBBS, PhD
Pei Hui, PhD, MD
96Publications
3,446Citations
Breast Neoplasms
Immunohistochemistry
Thyroid Gland
Breast
Publications
2024
Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer.
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 10668969241256109. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchAltmetricConceptsBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival timeFibroepithelial Neoplasm with Hybrid Features of Benign Phyllodes Tumor, Juvenile Papillomatosis, and Juvenile Fibroadenoma: A Case Report.
Liu B, Mehrotra M, Kowtha L, Guan M, Houldsworth J, Baskovich B, Harigopal M. Fibroepithelial Neoplasm with Hybrid Features of Benign Phyllodes Tumor, Juvenile Papillomatosis, and Juvenile Fibroadenoma: A Case Report. International Journal Of Surgical Pathology 2024, 10668969241256112. PMID: 38839253, DOI: 10.1177/10668969241256112.Peer-Reviewed Original ResearchConceptsBenign phyllodes tumorPhyllodes tumorJuvenile fibroadenomaJuvenile papillomatosisFibroepithelial lesionsFibroepithelial neoplasmsFamily history of breast cancerHistory of breast cancerHyperplastic ductal epitheliumPapillary apocrine metaplasiaBreast cancer developmentMiddle-aged patientsProliferative breast tumorsHypoechoic solid massMicropapillary projectionsPreoperative biopsyBiphasic neoplasmPalpable massApocrine metaplasiaTumor featuresBreast tumorsCase reportDuctal epitheliumCellular fibroadenomaBreast cancerIdentification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition.
Lo Y, Lester S, Ellis I, Lanjewar S, Laurini J, Patel A, Bhattarai A, Ustun B, Harmon B, Kleer C, Ross D, Amin A, Wang Y, Bradley R, Turashvili G, Zeng J, Baum J, Singh K, Hakima L, Harigopal M, Komforti M, Shin S, Abbott S, Jaffer S, Badve S, Khoury T, D'Alfonso T, Ginter P, Collins V, Towne W, Gan Y, Nassar A, Sahin A, Flieder A, Aldrees R, Ngo M, Edema U, Sapna F, Schnitt S, Fineberg S. Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition. Archives Of Pathology & Laboratory Medicine 2024 PMID: 38244086, DOI: 10.5858/arpa.2023-0163-oa.Peer-Reviewed Original ResearchConceptsInvasive breast cancerWorld Health Organization definitionNottingham grading systemOrganization definitionMedian concordance rateMicropapillary carcinomaMucinous carcinomaInvasive carcinomaBreast pathologistsBreast cancerConcordance rateGrading systemCarcinomaTubulesPathologistsBreastConcordanceProfessor EllisCancerCases
2023
HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience
Podany P, Golastani R, Zhan H, Liang Y, Harigopal M, Krishnamurti U. HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience. American Journal Of Clinical Pathology 2023, 160: s9-s10. DOI: 10.1093/ajcp/aqad150.021.Peer-Reviewed Original ResearchConceptsLow HER2 expressionInvasive breast carcinomaIHC scoreHER2 expressionGroup 1Group 3HER2 immunohistochemistryHER2 testingGroup 2HER2 FISHGroup 4ASCO/CAP guidelinesGroup 5Single institutional experienceRecent clinical trialsStandard of careASCO/CAP 2018 guidelinesHER2/CEP17 ratioEquivocal HER2HER2 positivityTrastuzumab deruxtecanMore patientsCAP guidelinesPatient eligibilityCase reportPathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study
Zhan H, Fineberg S, Podany P, Zeng J, Wang Y, Harigopal M, Singh K. Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study. Human Pathology 2023, 142: 15-19. PMID: 37972873, DOI: 10.1016/j.humpath.2023.10.002.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsNeoadjuvant endocrine therapyResidual tumour cellularityNeoadjuvant chemotherapyNeoadjuvant therapyMucinous carcinomaPathologic responseEndocrine therapyPathological responseMucin poolsBreast cancerEstrogen receptorTumor cellularityAcellular mucin poolsFavorable histologic subtypePreoperative adjuvant therapyRetrospective cohort studyComplete pathologic responseInvasive breast cancerNET groupMulti-institutional studyNeoadjuvant HER2Adjuvant therapyMC patientsCohort studyPathologic reviewBreast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review.
Carrasco-Tenezaca F, Moreira-Dinzey J, Manrai P, Bearse M, Burela S, Podany P, Singh K, Pareja F, Zheng J, Muscato N, Liang Y, Zhan H, Krishnamurti U, Dolezal D, Wang J, Harigopal M. Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review. International Journal Of Surgical Pathology 2023, 10668969231209780. PMID: 37908113, DOI: 10.1177/10668969231209780.Peer-Reviewed Original ResearchConceptsBreast carcinomaTubulopapillary featuresHuman epidermal growth factor 2 (HER2) expressionBreast cancer histologic subtypesNonmetastatic breast carcinomaTriple-negative profileHigh-grade nuclear featuresTriple-negative carcinomasHigh-grade featuresMetastatic breast carcinomaGrowth factor 2 expressionFactor 2 expressionReports of tumorsMicropapillary projectionsNeoadjuvant therapyHistologic subtypeWorse prognosisFirst tumorPoor prognosisAdditional tumorsInvasive carcinomaEstrogen receptorCarcinomaPathogenic variantsTumorsThe correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumorsAI-Powered Biomolecular-Specific and Label-Free Multispectral Imaging Rapidly Detects Malignant Neoplasm in Surgically Excised Breast Tissue Specimens.
Pandey R, Fournier D, Root G, Riccio M, Shirvalkar A, Zamora G, Daigneault N, Sapack M, Zhong M, Harigopal M. AI-Powered Biomolecular-Specific and Label-Free Multispectral Imaging Rapidly Detects Malignant Neoplasm in Surgically Excised Breast Tissue Specimens. Archives Of Pathology & Laboratory Medicine 2023, 147: 1298-1306. PMID: 36730476, DOI: 10.5858/arpa.2022-0228-oa.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMalignant neoplasmsPredictive valueBreast tissueBreast conservation surgeryNormal breast tissueNegative predictive valuePositive predictive valueInitial gross examinationFresh tissue samplesResection marginsConservation surgeryCosmetic outcomeBreast cancerIntraoperative usePathology evaluationGross examinationBreast specimensFrozen sectionsNeoplasmsTissue blocksTissue samplesLumpectomy specimensMargin assessmentSurgeon's handObjective toolMulti-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
Robbins C, Fernandez A, Han G, Wong S, Harigopal M, Podoll M, Singh K, Ly A, Kuba M, Wen H, Sanders M, Brock J, Wei S, Fadare O, Hanley K, Jorns J, Snir O, Yoon E, Rabe K, Soong T, Reisenbichler E, Rimm D. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. Modern Pathology 2023, 36: 100032. PMID: 36788069, PMCID: PMC10278086, DOI: 10.1016/j.modpat.2022.100032.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOverall percent agreementHuman epidermal growth factor 2HER2 IHCReal-world settingEpidermal growth factor 2HER2-negative statusBreast cancer biopsiesCompanion diagnostic testsMulti-institutional assessmentGrowth factor 2Breast cancerImmunohistochemistry assaysCancer biopsiesHER2 immunohistochemistryPathologist concordanceIHCClinical standardsPercent agreementDiagnostic testsSubstantial discordanceERBB2 geneInterrater reliabilityPathologistsFactor 2ConcordanceSignificance of Myoepithelial Cell Layer in Breast Ductal Carcinoma in situ With Papillary Architecture With and Without Associated Invasive Carcinoma
Golestani R, Singh K, Karam P, Pinto M, Liang Y, Orsaria M, Harigopal M. Significance of Myoepithelial Cell Layer in Breast Ductal Carcinoma in situ With Papillary Architecture With and Without Associated Invasive Carcinoma. Clinical Breast Cancer 2023, 23: 91-100. DOI: 10.1016/j.clbc.2022.09.006.Peer-Reviewed Original ResearchCitationsConceptsSolid papillary carcinomaPapillary DCISInvasive carcinomaMyoepithelial cellsPapillary architecturePapillary carcinomaConventional invasive carcinomaFoci of DCISPapillary breast lesionsAssociated invasive carcinomaBreast ductal carcinomaME cellsMyoepithelial cell layerCell layerMedian followDistant metastasisHistologic evidenceDuctal carcinomaME cell layersPathology databasePapillary componentRetrospective searchResults MajorityCarcinomaDCIS
Academic Achievements and Community Involvement
honor HPV Investigation Award
National AwardAmerican Society of CytopathologyDetails08/29/2016United Statesactivity Member
Professional OrganizationsPapanikolaou SocietyDetails07/31/2014 - 08/29/2016DescriptionEducation committee for national residency and cytotechnology programs
Links & Media
News
- May 31, 2022
Uma Krishnamurti, MBBS, MD, PhD, Named New Director of Yale Breast Pathology
- October 13, 2021
Breast Cancer Awareness Q&A with Pathologist Malini Harigopal, MD
- May 29, 2020Source: Nature Medicine
Nature Medicine's COVID-19 Research in Brief: 9 May to 15 May, 2020
- June 01, 2015
Breast cancer study finds it helps to remove more tissue
Get In Touch
Contacts
Locations
Department of Pathology
Academic Office
Clinic Building
789 Howard Avenue, Ste CB 505A
New Haven, CT 06519
Fax
203.785.2641Appointments
203.785.3753